DNA-based delivery of G-CSF as a durable and efficacious approach to treat severe chronic neutropenia

Document Type

Article

Publication Date

3-27-2025

Publication Title

Molecular Therapy

Abstract

Many potent biologics are limited by their short half-lives, necessitating frequent administration, which can be burdensome for patients and economically costly. Granulocyte-colony stimulating factor (G-CSF), a critical treatment for severe chronic neutropenia (SCN), known under the generic drug name filgrastim, exemplifies this challenge. SCN patients often require daily doses of G-CSF, which can adversely affect compliance and highlights the need for improved therapeutic strategies. Intramuscular electroporation (IM-EP) of DNA medicines has emerged as a promising solution by facilitating continuous and long-lasting production of the encoded therapeutic protein. Here, we employ this technology for DNA-based delivery of G-CSF. The data from mouse models demonstrate that a single administration leads to an improved pharmacokinetic profile, durable gene expression beyond 1 year, and efficacy in a neutropenia disease model. Furthermore, results from rabbit models validate the scalability of this approach and confirm that muscle-derived G-CSF specifically increases neutrophil count without affecting other bone marrow-derived cell types. These findings underscore the potential of IM-EP of DNA medicines as an effective method to overcome the limitations posed by the short half-life of some biologics, offering a more patient-friendly and cost-effective therapeutic approach.

First Page

3257

Last Page

3269

DOI

10.1016/j.ymthe.2025.03.038

Rights

© 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Link to Full Text

Share

COinS